Research and Markets: Global Recurrent Glioblastoma Multiforme (GBM) Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/s6wgb3/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Agenus, Inc.
• Amgen Inc.
• AngioChem Inc.
• Apogenix GmbH
• AstraZeneca Plc
• Axelar AB
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• Bristol-Myers Squibb Company
• Celldex Therapeutics, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• EnGeneIC Ltd
• ERC Belgium SA
• GenSpera, Inc.
• GW Pharmaceuticals Plc
• ImmunoCellular Therapeutics, Ltd.
• Karyopharm Therapeutics, Inc.
• Les Laboratoires Servier SAS
• Medicenna Therapeutics, Inc
• Merck & Co., Inc.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Spectrum Pharmaceuticals, Inc.
• Threshold Pharmaceuticals, Inc.
• Tocagen Inc.
• TRACON Pharmaceuticals, Inc.
• Vascular Biogenics Ltd.
• Virttu Biologics Limited

For more information visit http://www.researchandmarkets.com/research/s6wgb3/recurrent

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005338/en/